Spiro Rombotis is President and Chief Executive Officer of Cyclacel Pharmaceuticals, Inc. He joined the company in August 1997 and has 29 years of experience with pharmaceutical and biotechnology companies. He was previously Vice President of International Operations and Business Development; Managing Director, Europe; and Director, Japanese joint venture, at The Liposome Company, Inc. He also served as Vice President of Pharmaceuticals for Central and Eastern Europe and as Director of International Marketing at Bristol-Myers Squibb. He was Head of European Marketing and Sales, Head of Corporate Development and one of the first employees of Centocor, Inc., and worked in business development at Novartis AG. He holds a B.A. from Williams College and an MBA and a master's degree in hospital management, with honors, from the Kellogg School of Management at Northwestern University, where he serves on the Kellogg biotech advisory board. He also serves on the board of trustees of BioNJ, the biotechnology industry trade group in New Jersey. Profile
TWST: Please begin with a brief historical sketch of Cyclacel Pharmaceuticals and a picture of its operations at the present time.
Mr. Rombotis: Cyclacel is a spinout of the University